Demand For Child Proton Therapy Insurance Coverage Growing In Japan
This article was originally published in PharmAsia News
With the growing demand for proton therapy increasing in Japan and the decreased physical impediments caused by radiation therapy, medical professionals demands are increasing for insurance coverage of proton therapy treatment of pediatric cancer.
You may also be interested in...
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.